Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 5
Submit an article Journal homepage
262
Views
17
CrossRef citations to date
0
Altmetric
Drug Profile

Erlotinib in the first-line treatment of non-small-cell lung cancer

Manolo D’Arcangelo Istituto Toscano Tumori, Ospedale Civile, Viale Alfieri 36, 57100, Livorno, Italy; University of Colorado Cancer Center, Aurora, CO, USA; Istituto Toscano Tumori, Ospedale Civile, Viale Alfieri 36, 57100, Livorno, Italy; University of Colorado Cancer Center, Aurora, CO, USA
&
Federico Cappuzzo Istituto Toscano Tumori, Ospedale Civile, Viale Alfieri 36, 57100, Livorno, Italy. [email protected]; Istituto Toscano Tumori, Ospedale Civile, Viale Alfieri 36, 57100, Livorno, Italy. [email protected]
Pages 523-533 | Published online: 10 Jan 2014

References

  • Goldstraw P, Crowley J, Chansky K et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J. Thorac. Oncol. 2(8), 706–714 (2007).
  • Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(21), 3543–3551 (2008).
  • Grønberg BH, Bremnes RM, Fløtten O et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 27(19), 3217–3224 (2009).
  • Sandler A, Gray R, Perry MC et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542–2550 (2006).
  • Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol. 27(8), 1227–1234 (2009).
  • Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu. Rev. Med. 55, 433–457 (2004).
  • Johnson JR, Cohen M, Sridhara R et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin. Cancer Res. 11(18), 6414–6421 (2005).
  • Meany HJ, Fox E, McCully C, Tucker C, Balis FM. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. Cancer Chemother. Pharmacol. 62(3), 387–392 (2008).
  • Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28(Suppl. 1), S24–S31 (2009).
  • Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr. Relat. Cancer 12(Suppl. 1), S17–S27 (2005).
  • Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J. Clin. Oncol. 26(10), 1742–1751 (2008).
  • Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358(11), 1160–1174 (2008).
  • Yun CH, Boggon TJ, Li Y et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11(3), 217–227 (2007).
  • Rukazenkov Y, Speake G, Acheson K et al. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? Anticancer. Drugs 20(10), 856–866 (2009).
  • Speake G, Anderton J, Acheson K et al. A pharmacological comparison of gefitinib and erlotinib. Presented at: 97th American Association of Cancer Research Annual Meeting. Washington, DC, USA. Poster 3784 (2006).
  • Yuza Y, Glatt KA, Jiang J et al. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol. Ther. 6(5), 661–667 (2007).
  • Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 25(5), 587–595 (2007).
  • Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97(5), 339–346 (2005).
  • Tokumo M, Toyooka S, Kiura K et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res. 11(3), 1167–1173 (2005).
  • Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin. Cancer Res. 12(24), 7232–7241 (2006).
  • Giaccone G, Gallegos Ruiz M, Le Chevalier T et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a Phase II study. Clin. Cancer Res. 12(20 Pt 1), 6049–6055 (2006).
  • Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T. A Phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J. Thorac. Oncol. 4(2), 214–219 (2009).
  • Lilenbaum R, Axelrod R, Thomas S et al. Randomized Phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J. Clin. Oncol. 26(6), 863–869 (2008).
  • Gridelli C, Ciardiello F, Gallo C et al. First-line erlotinib followed by second-line cisplatin–gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J. Clin. Oncol. 30(24), 3002–3011 (2012).
  • Thomas M, Reuss A, Fischer JR et al. Innovations: randomized Phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J. Clin. Oncol. 29(Suppl. 15), Abstract 7504 (2011).
  • Lee SM, Khan I, Upadhyay S et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, Phase 3 trial. Lancet Oncol. 13(11), 1161–1170 (2012).
  • Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947–957 (2009).
  • Lee JS, Park K, Kim SW et al. A randomized Phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J. Thor. Oncol. 4(Suppl. 19) Abstract PRS 4 (2009).
  • Mitsudomi T, Morita S, Yatabe Y et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121–128 (2010).
  • Maemondo M, Inoue A, Kobayashi K et al.; North-East Japan Study Group.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380–2388 (2010).
  • Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735–742 (2011).
  • Rosell R, Moran T, Queralt C et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958–967 (2009).
  • Rosell R, Carcereny E, Gervais R et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239–246 (2012).
  • Rosell R, Massuti Sureda B, Costa C et al. Concomitant actionable mutations and overall survival (OS) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) included in the EURTAC trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (v3). Ann. Oncol. 23(Suppl. 10), Abstract LBA31 (2012).
  • Rosell R, Molina-Vila MA, Taron M et al. EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (P) in the EURTAC study. J. Clin. Oncol. 30(Suppl.), Abstract 7522 (2012).
  • Su KY, Chen HY, Li KC et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30(4), 433–440 (2012).
  • Sun Y, Wu YL, Zhou CC et al. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study. Lung Cancer 79(2), 143–150 (2013).
  • Yauch RL, Januario T, Eberhard DA et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 11(24 Pt 1), 8686–8698 (2005).
  • Suzuki T, Nakagawa T, Endo H et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’) is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer 42(1), 35–41 (2003).
  • Jackman DM, Yeap BY, Lindeman NI et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J. Clin. Oncol. 25(7), 760–766 (2007).
  • Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2(1), 0058–0061 (2005).
  • Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 13(10), 2890–2896 (2007).
  • Linardou H, Dahabreh IJ, Kanaloupiti D et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9(10), 962–972 (2008).
  • Mao C, Qiu LX, Liao RY et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 69(3), 272–278 (2010).
  • Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23(25), 5900–5909 (2005).
  • Brugger W, Triller N, Blasinska-Morawiec M et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 29(31), 4113–4120 (2011).
  • Miller VA, O’Connor P, Soh C, Kabbinavar F; for the ATLAS Investigators. A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 27(Suppl.), Abstract LBA8002 (2009).
  • Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Thorac. Oncol. 7(2), 316–322 (2012).
  • Douillard JY, Shepherd FA, Hirsh V et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized Phase III INTEREST trial. J. Clin. Oncol. 28(5), 744–752 (2010).
  • Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 1. J. Clin. Oncol. 22(5), 777–784 (2004).
  • Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 2. J. Clin. Oncol. 22(5), 785–794 (2004).
  • Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25(12), 1545–1552 (2007).
  • Herbst RS, Prager D, Hermann R et al.; TRIBUTE Investigator Group. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892–5899 (2005).
  • Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin. Lung Cancer 7(6), 385–388 (2006).
  • Mok TS, Wu YL, Yu CJ et al. Randomized, placebo-controlled, Phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 27(30), 5080–5087 (2009).
  • Mok T, Wu YL, Thongprasert S et al. A randomized placebo-controlled Phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II. J. Clin. Oncol. 30(Suppl.), Abstract 7519 (2012).
  • Mok TSK, Lee JS, Zhang L et al. Biomarker analyses and overall survival (OS) from the randomized, placebo-controlled, phase 3, FASTACT-2 study of intercalated erlotinib with first-line chemotherapy in advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 23(Suppl. 9), Abstract 12260 (2012).
  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123–132 (2005).
  • Cappuzzo F, Ciuleanu T, Stelmakh L et al.; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase 3 study. Lancet Oncol. 11(6), 521–529 (2010).
  • Reck M, van Zandwijk N, Gridelli C et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global Phase IV Tarceva Lung Cancer Survival Treatment study. J. Thorac. Oncol. 5(10), 1616–1622 (2010).
  • Mok T, Wu YL, Au JS et al. Efficacy and safety of erlotinib in 1242 east/south-east Asian patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 5(10), 1609–1615 (2010).
  • Strauss GM, Herndon JE 2nd, Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J. Clin. Oncol. 26(31), 5043–5051 (2008).
  • Arriagada R, Dunant A, Pignon JP et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J. Clin. Oncol. 28(1), 35–42 (2010).
  • Goss GD, Lorimer I, Tsao MS et al. A Phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. J. Clin. Oncol. 28(18 Suppl.), Abstract LBA7005 (2010).
  • Kelly K, Chansky K, Gaspar LE et al. Updated analysis of SWOG 0023: A randomized Phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. J. Clin. Oncol. 25(18 Suppl.), Abstract 7513 (2007).
  • Neal JW, Pennell NA, Govindan R et al. The SELECT study: A multicenter Phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 30(Suppl), Abstract 7010 (2012).
  • Janjigian YY, Park BJ, Zakowski MF et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J. Thorac. Oncol. 6(3), 569–575 (2011).
  • Hesketh PJ, Chansky K, Wozniak AJ et al. Southwest Oncology Group Phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J. Thorac. Oncol. 3(9), 1026–1031 (2008).
  • Lee DH, Kim SW, Suh C, Han YH, Lee JS. Phase II study of erlotinib for chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets. Cancer Chemother. Pharmacol. 67(1), 35–39 (2011).
  • Pallis AG, Voutsina A, Kentepozidis N et al. A Phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer. Clin. Lung Cancer 13(2), 129–135 (2012).
  • Chen YM, Tsai CM, Fan WC et al. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older. J. Thorac. Oncol. 7(2), 412–418 (2012).
  • Stinchcombe TE, Peterman AH, Lee CB et al. A randomized Phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age =70 years) with stage IIIB/IV non-small cell lung cancer. J. Thorac. Oncol. 6(9), 1569–1577 (2011).
  • Fukuoka M, Wu YL, Thongprasert S et al. Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29(21), 2866–2874 (2011).
  • Mitsudomi T, Morita S, Yatabe Y et al. Updated overall survival results of WJTOG 3405, a randomized Phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J. Clin. Oncol. 30(Suppl.), Abstract 7521 (2012).
  • Inoue A, Kobayashi K, Maemondo M et al. Updated overall survival results from a randomized Phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann. Oncol. doi:10.1093/annonc/mds214 (2012) (Epub ahead of print).
  • Yang JCH, Schuler MH, Yamamoto N et al. LUX-Lung 3: A randomized, open-label, Phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J. Clin. Oncol. 30(Suppl.), Abstract LBA7500 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.